MaaT Pharma Faces Regulatory Hurdles with MaaT013 Approval

MaaT Pharma SACA is under scrutiny from First Berlin Equity Research, as analyst Christian Orquera places the company’s rating under review. This follows a 'negative trend' opinion from the EMA's CHMP regarding the conditional marketing authorisation of MaaT013 for acute GvHD. A formal CHMP vote is anticipated in June 2026, with MaaT Pharma having 15 days post-vote to appeal, which they firmly intend to pursue.

The contention revolves around the trial methodology of the ARES study, focusing on isolating MaaT013's treatment effect in its single-arm design rather than clinical benefit. This re-examination may be guided by a panel of haemato-oncologists, potentially acknowledging unmet medical needs alongside methodological considerations. Strategic levers for the appeal include precedents like Adstiladrin and Rezurock, and challenges in conducting traditional randomized studies in this setting.